Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04295759 · ClinicalTrials.gov registry record · Phase 1
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04295759 is a Phase 1 study that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 13 participants.
The verdict
NCT04295759, a Phase 1 study, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
Interventions
- DRUG INCB7839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04295759
The ClinicalTrials.gov registry entry for NCT04295759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB7839 is the first listed.
NCT04295759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04295759 about?
NCT04295759 is a clinical study titled "INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas". This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
What is the current status of trial NCT04295759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-07-27. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT04295759?
The interventions under investigation include: INCB7839 (DRUG).
Who is sponsoring clinical trial NCT04295759?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.